FDA Expands AbbVie’s (ABBV) Qulipta Label in Chronic Migraine

Title: FDA Expands AbbVie’s Qulipta Label to Treat Chronic Migraine


Migraine is a neurological condition with no cure affecting over 39 million Americans. Chronic migraine, which involves experiencing headaches for 15 days or more within a 30-day period, can be especially debilitating. However, the recent US Food and Drug Administration (FDA) approval of AbbVie’s Qulipta offers new hope for those suffering from chronic migraine.

Key Point 1: Understanding Chronic Migraine

Introduce what chronic migraine is and the impact it has on quality of life. Discuss how treatment options for chronic migraine have been limited and usually offer only partial relief.

Key Point 2: The Role of Qulipta in Chronic Migraine Treatment

Introduce Qulipta, a newly approved medication by the FDA, as a potential treatment option for chronic migraine. Discuss how Qulipta works, what benefits it offers, and how it differs from current treatments.

Key Point 3: The FDA Approval of Qulipta

Highlight the recent approval by the FDA to expand Qulipta’s label for the treatment of chronic migraine in adults. Discuss the criteria for approval and what it means for the medical community and patients.

Key Point 4: The Benefits of Qulipta

Discuss the benefits of Qulipta over current treatments for chronic migraine. Highlight how Qulipta offers relief with fewer side effects than current treatments and how it offers hope for those who have not experienced relief with other treatments.

Key Point 5: Future of Chronic Migraine Treatment

Discuss the potential impact of Qulipta and the continued need for research and development in chronic migraine treatment. Highlight how new treatments like Qulipta can help improve the quality of life for those suffering from chronic migraine and the potential for curing this neurological condition altogether.


Sum up the key points discussed in the blog post, emphasizing the hope and potential Qulipta offers as a new treatment option for chronic migraine. Reinforce the importance of continued research and development in chronic migraine treatment and the hope for a cure for this debilitating condition.